Latest Eisai Co. Ltd. Stories
Tokyo, Apr 22, 2011 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) announced today that it has received approval to market its novel anticancer Halaven(R) Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer.
Tokyo, Sept 29, 2010 - (JCN Newswire) - Eisai Co., Ltd. and Shinshu University venture company Anaeropharma Science, Inc.
Tokyo, Sept 30, 2010 - (JCN Newswire) - Brain Factory Co., Ltd. and Eisai Co., Ltd. announced today that they have concluded a license agreement concerning a dihydrogen phosphonoxy methoxy derivative of ravuconazole (ravuconazole prodrug).
Tokyo, Sept 7, 2010 - (JCN Newswire) - SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd.
Tokyo, Sept 2, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease.
Tokyo, Aug 24, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today that results of a Phase III study in epilepsy patients with refractory partial seizures demonstrate the clinical benefits of the novel investigational compound E2007 (generic name: perampanel).
EXTON, Pa., Sept.
EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc.
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S.
- Large; stout; burly.